Global Pulmonary Drugs Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Class;

Beta-2 Agonists, Anticholinergic Agents, Oral and Inhaled Corticosteroids, and Others.

By Indication;

Asthma, COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn804783498 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Pulmonary Drugs Market (USD Million), 2021 - 2031

In the year 2023, the Global Pulmonary Drugs Market was valued at USD 6,617.49 million. The size of this market is expected to increase to USD 8,419.30 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 3.5%.

The global pulmonary drugs market is witnessing a transformative phase driven by advancements in drug delivery technologies, growing prevalence of respiratory diseases, and a burgeoning demand for effective treatments. Pulmonary drug therapies play a crucial role in managing respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and pulmonary arterial hypertension (PAH), among others. With an increasing emphasis on personalized medicine and targeted therapies, the pulmonary drugs market is poised for substantial growth and innovation.

Factors such as rising air pollution levels, lifestyle changes, aging populations, and a higher incidence of smoking-related illnesses continue to fuel the demand for pulmonary medications worldwide. The advent of novel biologics, combination therapies, and inhalation devices offers new avenues for disease management and improved patient outcomes. Against this backdrop, pharmaceutical companies, in collaboration with device manufacturers, are striving to develop innovative solutions that address unmet medical needs and enhance the quality of life for individuals suffering from respiratory disorders. As research endeavors intensify and regulatory frameworks evolve, the global pulmonary drugs market is positioned to witness significant expansion, catering to the growing healthcare needs of populations across the globe.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Indication
    3. Market Snapshot, By Region
  4. Global Pulmonary Drugs Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Technological Advancements in Drug Delivery Systems

        2. Increasing Prevalence of Respiratory Diseases

        3. Growing Demand for Personalized and Targeted Therapies

      2. Restraints
        1. Stringent Regulatory Approval Processes

        2. High Development Costs Associated with Novel Therapies

        3. Concerns Regarding Drug Safety and Adverse Effects

      3. Opportunities
        1. Collaboration with Pharmaceutical Companies for Combination Therapies

        2. Expansion into Emerging Markets with Untapped Potential

        3. Development of Biologic Therapies for Respiratory Disorders

    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Pulmonary Drugs Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Beta-2 Agonists

      2. Anticholinergic Agents

      3. Oral

      4. Inhaled Corticosteroids

      5. Others

    2. Global Pulmonary Drugs Market, By Indication, 2021 - 2031 (USD Million)
      1. Asthma

      2. COPD

      3. Allergic Rhinitis

      4. Pulmonary Arterial Hypertension

      5. Cystic Fibrosis

      6. Others

    3. Global Pulmonary Drugs Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Boehringer Ingelheim
      2. Merck & Co.
      3. AstraZeneca PLC
      4. GlaxoSmithKline PLC
      5. Grifols, S.A.
  7. Analyst Views
  8. Future Outlook of the Market